News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Addex Therapeutics (ADXN.SW) and National Institute on Drug Abuse (NIDA) Enter Collaboration to Advance ADX71441 & ADX88178 in Drug Abuse and Addiction


11/4/2013 9:39:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development announced today entering a collaboration with the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) to evaluate the pharmacology of ADX71441, a GABAB receptor positive allosteric modulator (PAM), and ADX88178, an mGlu4 PAM in preclinical models of drug abuse and addiction. The collaboration will evaluate Addex drug candidates, ADX71441 and ADX88178 in a battery of preclinical models to study their potential as treatments for nicotine and cocaine addiction.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES